BioXell’s development program is based on three separate technological platforms.

The VD3 platform, at the core of BioXell’s expertise in urology and inflammation since the spin off from Roche, has yielded a lead product candidate, Elocalcitol, in clinical development for three urological indications, and a second product candidate, BXL746, to enter Phase IIa trials in post-surgical adhesions in 2008.

MNAC13, in-licensed from Lay Line Genomics, is a fully humanized antibody against TrkA which has the potential to become a novel and promising approach to treating pain.

The TREM platform, based on a discovery by a member of BioXell’s Scientific Advisory Board, is composed of a novel family of receptors with a key role in several inflammatory conditions.